论文部分内容阅读
目的观察依折麦布对高脂血症合并肝损伤患者的疗效。方法单纯高胆固醇血症合并肝损伤(A组,30例)和混合型高脂血症合并肝损伤(B组,35例)患者服用依折麦布10mg/d;用酶法测定治疗前及治疗4、8周时的血清AST、ALT、肌酸激酶(CK)、血LDL-C、TC和TG水平。结果与治疗前比较,依折麦布治疗8周时,B组AST、ALT、CK明显下降(P<0.05),两组LDL-C、TC、TG水平均明显下降,B组下降更明显(P<0.05)。结论依折麦布单药治疗高脂血症合并肝损伤患者安全、有效。
Objective To observe the efficacy of ezetimibe in patients with liver injury due to hyperlipidemia. Methods Patients with hypercholesterolemia complicated with liver injury (group A, 30 cases) and mixed type hyperlipidemia with liver injury (group B, 35 cases) were treated with 10 mg / day of ezetimibe; Serum AST, ALT, creatine kinase (CK), blood LDL-C, TC and TG levels at 4 and 8 weeks after treatment. Results Compared with those before treatment, the levels of AST, ALT and CK in group B were significantly decreased (P <0.05) at 8 weeks after ezetimibe treatment. The levels of LDL-C, TC and TG decreased significantly in group B and decreased more significantly in group B P <0.05). Conclusion Ezetimibe is safe and effective in the treatment of patients with liver injury due to hyperlipidemia.